Cell and Gene Commercialization

  1. From Laboratory To Launchpad: Japan's Cell And Gene Therapy Ecosystem Hits Its Stride 10/21/2026

    Japan is emerging as a credible cell and gene therapy hub as regulation, manufacturing, and capital advance, despite gaps in funding, talent, risk culture, and language.

  2. Uncovering The Potential Of Exosomes 10/16/2026

    Exosomes show early promise as drugs and drug carriers, but limited understanding of how their characteristics relate to function complicates isolating specific populations and scaling production.

  3. Viral Vector Production: How CDMOs Influence Late-Stage Development Success 10/16/2026

    Late-stage viral vector programs leave almost no margin for error. Regulatory, operational, and market pressures shape the path to commercial launch, and the choice of manufacturing partner carries real weight.

  4. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

    Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

  5. Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing Success 10/13/2026

    Cell therapy programs often stall between clinical and commercial supply because of manufacturing readiness, not clinical performance. Five recurring pitfalls, from partner choice to automation, show where early planning matters.

  6. Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026 10/12/2026

    At Meeting on the Mesa 2026, industry leaders discussed what it will take to move autoimmune CAR T beyond promising clinical results.

  7. Bridging Binder Discovery And Automated CAR T Cell Manufacturing 10/8/2026

    CLDN6-targeting CAR T cells for solid tumors move from binder discovery through manufacturing, with attention to how process design shapes technology transfer and consistency.

  8. Building The Infrastructure Behind Cell Therapy Manufacturing 10/2/2026

    A small automation shop focused on cell therapy manufacturing grew into a platform covering equipment, consumables, software, and industrialization services for commercial-scale production runs.

  9. Scaling Cryopreservation Without Wasting MSC Product 10/2/2026

    During this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. turn the discussion to the practical challenges of cryopreserving large cell volumes, manufacturing capacity, and how companies can avoid introducing major changes as they move toward commercialization.

  10. When Small Process Changes Become A Different MSC Product 10/2/2026

    During this final segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover a particularly strong manufacturing point. Even seemingly minor changes in cell culture, processing, or expansion can accumulate and create product drift, raising the question of when a modified process produces what is effectively a different cell therapy.